U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559019) titled 'Safety and Preliminary Activity of BI115 in Advanced SCLC' on April 24.
Brief Summary: This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer (SCLC)
Intervention:
DRUG: IBI115
IBI115 will be administered. The Dose Limiting Toxicity (DLT) observation period will last for 28 or 21 days after first dose. After completion of the DLT observation period, subject will continue to receive IBI11...